Roivant Sciences Ltd. (ROIV)
| Market Cap | 21.34B +171.1% |
| Revenue (ttm) | 8.26M -71.6% |
| Net Income | -299.77M |
| EPS | -0.54 |
| Shares Out | 719.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,294,167 |
| Open | 29.98 |
| Previous Close | 29.96 |
| Day's Range | 29.31 - 30.35 |
| 52-Week Range | 10.59 - 32.79 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 39.04 (+30.22%) |
| Earnings Date | May 20, 2026 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rh... [Read more]
Financial Performance
In fiscal year 2026, Roivant Sciences's revenue was $8.26 million, a decrease of -71.57% compared to the previous year's $29.05 million. Losses were -$299.77 million, 74.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ROIV stock is "Strong Buy." The 12-month stock price target is $39.04, which is an increase of 30.22% from the latest price.
News
Roivant Sciences price target raised to $40 from $35 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Roivant Sciences (ROIV) to $40 from $35 and keeps an Overweight rating on the shares. The firm updated the company’s…
Roivant Sciences price target raised to $36 from $30 at Guggenheim
Guggenheim analyst Yastin Suneja raised the firm’s price target on Roivant Sciences (ROIV) to $36 from $30 and keeps a Buy rating on the shares. The firm updated its model…
Roivant Sciences price target raised to $31.50 from $29.50 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $31.50 from $29.50 and keeps a Neutral rating on the shares. The firm updated the company’s…
Roivant Sciences price target raised to $41 from $38 at TD Cowen
TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $38 and keeps a Buy rating on the shares. The firm said IMVT-1402 toplined impressive Ph2b…
Roivant Sciences price target raised to $42 from $35 at Citi
Citi raised the firm’s price target on Roivant Sciences (ROIV) to $42 from $35 and keeps a Buy rating on the shares. The firm sees further share upside on Roivant’s…
Roivant Sciences rises 15.2%
Roivant Sciences (ROIV) is up 15.2%, or $4.28 to $32.49.
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.
Roivant Sciences rises 11.7%
Roivant Sciences (ROIV) is up 11.7%, or $3.30 to $31.51.
Roivant Sciences Q4 Earnings Call Highlights
Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary h...
Roivant Sciences Earnings Call Transcript: Q4 2026
Strong clinical progress with high response rates in refractory RA, rapid enrollment across programs, and robust cash position. Key launches and pivotal data readouts expected in the next 12 months, with significant commercial and regulatory milestones ahead.
Roivant Sciences Annual report: Q4 2026
Roivant Sciences has published its Q4 2026 annual report on May 20, 2026.
Roivant Sciences Slides: Q4 2026
Roivant Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 20, 2026.
Roivant Sciences Earnings release: Q4 2026
Roivant Sciences released its Q4 2026 earnings on May 20, 2026, summarizing the period's financial results.
Roivant Sciences reports Q4 EPS 28c, consensus (35c)
Reports Q4 revenue $2.52M, consensus $3.91M. “The positive Period 1 data from the IMVT-1402 trial in D2T RA demonstrate exciting potential for a new, differentiated mechanism to treat RA patients…
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, an...
Roivant Sciences price target raised to $29.50 from $29 at BofA
BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $29.50 from $29 and keeps a Neutral rating on the shares. The firm’s new target reflects…
Roivant Sciences Transcript: Bank of America Global Healthcare Conference 2026
The discussion highlighted a strategic shift toward multi-indication immunology franchises, robust capital allocation with a focus on shareholder returns, and a "ruthlessly economic" R&D approach. Key launches include brepocitinib for dermatomyositis and a broad FcRn pipeline, with Graves' disease as a major opportunity.
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, M...
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and prov...
Roivant Sciences participates in a conference call with JPMorgan
Conference call with management will be held on April 22 at 12 pm hosted by JPMorgan.
Roivant Sciences assumed with an Overweight at Piper Sandler
Piper Sandler assumed coverage of Roivant Sciences (ROIV) with an Overweight rating with a price target of $40, up from $22. The firm notes Roivant has traded up about 190%-plus…
Roivant Sciences price target raised to $34 from $30 at Jefferies
Jefferies analyst Dennis Ding raised the firm’s price target on Roivant Sciences (ROIV) to $34 from $30 and keeps a Buy rating on the shares. A key question post the…
Roivant Sciences Transcript: Study result
A new combined phase II-B/III trial for brepocitinib in lichen planopilaris has begun, targeting a severe, high-unmet-need scalp disorder with no approved therapies. The phase III TED study for batoclimab did not meet its primary endpoint, but data support ongoing Graves’ disease programs with next-generation FcRn inhibitors.
Roivant Sciences Press release: Study result
Roivant Sciences issued a press release on April 2, 2026, disclosing material business information to investors.
Roivant Sciences Slides: Study result
Roivant Sciences has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.